Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Laboratory Methods for the Clinical Follow up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead Publisher



Aru B1 ; Soltani M2 ; Pehlivanoglu C3 ; Gurlu E4 ; Ganjalikhanihakemi M2 ; Yanikkaya Demirel G1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey
  2. 2. Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Emergency Medicine, Hatay Training and Research Hospital, Antakya, Turkey
  4. 4. Year Student, Yeditepe University, Istanbul, Turkey

Source: Frontiers in Oncology Published:2022


Abstract

The development of immune checkpoint inhibitors, the monoclonal antibodies that modulate the interaction between immune checkpoint molecules or their ligands on the immune cells or tumor tissue has revolutionized cancer treatment. While there are various studies proving their efficacy in hematological malignancies, there is also a body of accumulating evidence indicating that immune checkpoint inhibitors’ clinical benefits are limited in such diseases. In addition, due to their regulatory nature that balances the immune responses, blockade of immune checkpoints may lead to toxic side effects and autoimmune responses, and even primary or acquired resistance mechanisms may restrict their success. Thus, the need for laboratory biomarkers to identify and monitor patient populations who are more likely respond to this type of therapy and the management of side effects seem critical. However, guidelines regarding the use of immune checkpoint inhibitors in hematological cancers and during follow-up are limited while there is no consensus on the laboratory parameters to be investigated for safety and efficacy of the treatment. This review aims to provide an insight into recent information on predictive and prognostic value of biomarkers and laboratory tests for the clinical follow up of hematological malignancies, with an emphasis on leukemia. Copyright © 2022 Aru, Soltani, Pehlivanoglu, Gurlu, Ganjalikhani-Hakemi and Yanikkaya Demirel.
Related Docs
View other Related Docs
1. Nivolumab Plus Ipilimumab Combination Therapy in Cancer: Current Evidence to Date, International Immunopharmacology (2023)
2. Immune Checkpoint Inhibition for the Treatment of Cancers: An Update and Critical Review of Ongoing Clinical Trials, Clinical Immunology (2021)
3. The Role of Bone Marrow Microenvironment (Bmm) Cells in Acute Myeloid Leukemia (Aml) Progression: Immune Checkpoints, Metabolic Checkpoints, and Signaling Pathways, Cell Communication and Signaling (2023)
4. Immune Checkpoint Inhibitors As Mediators for Immunosuppression by Cancer-Associated Fibroblasts: A Comprehensive Review, Frontiers in Immunology (2022)
5. Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination With Checkpoint Inhibitors and Beyond, Current Drug Targets (2022)
6. Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot, Cancer Communications (2024)
7. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
8. Targeting Immune Checkpoints: How to Use Natural Killer Cells for Fighting Against Solid Tumors, Cancer Communications (2023)
Experts (# of related papers)
View all Related Experts
Mazdak Ganjalikhani Hakemi (8)
Marzieh Rezaei (3)
Other Related Docs
9. An in Silico Investigation on the Binding Site Preference of Pd-1 and Pd-L1 for Designing Antibodies for Targeted Cancer Therapy, PLoS ONE (2024)
10. Leukemia Markers Expression of Peripheral Blood Vs. Bone Marrow Blasts Using Flow Cytometry, Medical Science Monitor (2003)
11. Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy, International Immunopharmacology (2022)
12. Research Paper: Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Basic and Clinical Neuroscience (2020)
13. Mrna-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients, Vaccines (2021)
14. Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities, Current Cancer Drug Targets (2022)
15. The Role of Tim-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?, Frontiers in Oncology (2020)
16. Immune Evader Cancer Stem Cells Direct the Perspective Approaches to Cancer Immunotherapy, Stem Cell Research and Therapy (2022)
17. Tim-3 in Leukemia; Immune Response and Beyond, Frontiers in Oncology (2021)
18. Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy, Frontiers in Oncology (2022)
19. Pd-1/Pd-L1 Interaction Regulates Bcl2, Ki67, Bax, and Casp3, Altering Proliferation, Survival, and Apoptosis in Acute Myeloid Leukemia, Iranian Journal of Allergy, Asthma and Immunology (2023)
20. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
21. A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis, Current Therapeutic Research - Clinical and Experimental (2024)
22. A Systematic Review Evaluating the Efficacy of Autologous Hematopoietic Transplantation for Diffuse Large B Cell Lymphoma-Type Richter Syndrome, Caspian Journal of Internal Medicine (2023)
23. The Relationship Between Programmed Cell Death Receptor-1 Expression in Colon Tumoral Tissue and Clinical and Pathological Characteristics of Patients With Colon Cancer; [ارتباط بیان گیرنده ی مرگ برنامه ریزی شده 1 در بافت تومورال روده ی بزرگ با ویژگی های بالینی و آسیب شناسی بیماران مبتلا به سرطان روده ی بزرگ], Journal of Isfahan Medical School (2023)